Vaxart, Inc. Files 8-K for Material Definitive Agreement

TL;DR

Vaxart just signed a big deal, filing an 8-K. Keep an eye on this one.

AI Summary

On February 7, 2025, Vaxart, Inc. entered into a Material Definitive Agreement. The company, previously known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS, is headquartered at 170 Harbor Way, Suite 300, South San Francisco, CA 94080. This filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This 8-K filing indicates Vaxart, Inc. has entered into a significant agreement, which could impact its business operations and future prospects.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities, the specifics of which are not detailed in this initial filing.

Key Numbers

• 001-35285 — SEC File Number (Identifies Vaxart, Inc.'s filing with the SEC.)
• 59-1212264 — IRS Employer Identification No. (Vaxart, Inc.'s tax identification number.)

Key Players & Entities

• Vaxart, Inc. (company) — Registrant
• Aviragen Therapeutics, Inc. (company) — Former Company Name
• Biota Pharmaceuticals, Inc. (company) — Former Company Name
• NABI BIOPHARMACEUTICALS (company) — Former Company Name
• February 7, 2025 (date) — Date of earliest event reported
• 170 Harbor Way, Suite 300 (address) — Principal Business Address
• South San Francisco, California (location) — Principal Business Address City and State
• 94080 (zip_code) — Principal Business Address Zip Code

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
• $240.1 m — available for payment to approximately $240.1 million, representing an increase of appr
• $105.9 million — presenting an increase of approximately $105.9 million. The Modification also clarifies the de

Filing Documents

• vxrt20250210_8k.htm (8-K) — 31KB
• ex_776577.htm (EX-10.1) — 464KB
• 0001437749-25-003319.txt ( ) — 663KB
• vxrt-20250207.xsd (EX-101.SCH) — 3KB
• vxrt-20250207_def.xml (EX-101.DEF) — 11KB
• vxrt-20250207_lab.xml (EX-101.LAB) — 15KB
• vxrt-20250207_pre.xml (EX-101.PRE) — 11KB
• vxrt20250210_8k_htm.xml (XML) — 3KB

01

Item 1.01 Entry into a Material Definitive Agreement. On February 7, 2025, Vaxart, Inc. (the "Company") entered into Modification No. 5 (the "Modification") to the ATI-RRPV Project Award Agreement No. 001, dated June 13, 2024 (the "Project Agreement"), with Advanced Technology International, the Rapid Response Partnership Vehicle's Consortium Management Firm funded by the Biomedical Advanced Research and Development Authority ("BARDA") of the U.S. Department of Health and Human Services. As previously disclosed, pursuant to the Project Agreement, the Company received funding to conduct a Phase 2b comparative study (the "Trial") evaluating the Company's oral pill COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the U.S. Food and Drug Administration. The Company previously announced that it had completed enrollment of the sentinel cohort portion of the study comprising approximately 400 patients comparing its oral pill XBB candidate against an mRNA XBB comparator and an independent data safety monitoring board recommended the study to proceed without modifications based on initial safety assessment of 30-day data from the sentinel cohort. The Modification increased the total amount of funding currently allotted to the Trial and available for payment to approximately $240.1 million, representing an increase of approximately $105.9 million. The Modification also clarifies the design of the Trial by specifying that the next portion of the Trial will compare the efficacy and safety of the Company's KP.2 oral vaccine candidate against an mRNA comparator directed against KP.2, and will be comprised of 10,000 participants. The Company is awaiting approval from BARDA to commence dosing in the Trial. The foregoing description of the Modification does not purport to be complete and is qualified in its entirety by reference to the full text of the Modification, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1* Modification No. 5, dated February 7, 2025, to the ATI-RRPV Project Award Agreement No. 001, dated June 13, 2024, between the Company and Advanced Technology International. 104 Cover Page Interactive Data File (embedded within Inline XBRL document). * Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted as (i) the Company has determined the omitted information is not material and (ii) the Company customarily and actually treats the omitted information as private or confidential.

Forward-Looking Statements

Forward-Looking Statements

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VAXART, INC. Dated: February 10, 2025 By: /s/ Phillip Lee Phillip Lee Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR